NCT01402401终止2 期
An Open-label, Single-arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination With Trastuzumab Standard Therapy as Second-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 21
- 试验地点
- 4
- 主要终点
- efficacy of AUY922 in combination with trastuzumab as assessed by RECIST
研究概览
简要总结
This study will assess the safety and efficacy of AUY922, when administered, in combination with trastuzumab in adult patients with HER2+ advanced gastric cancer, who have received trastuzumab plus chemotherapy in the first line.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients eligible for inclusion in this study have to meet all of the following criteria:
- •Written informed consent obtained prior to any screening procedures
- •Patients with documented cytological or histological confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and proven HER2 positive.
- •Patients with progressive disease (radiological confirmation required according to RECIST) after first line of trastuzumab in combination with chemotherapy for advanced gastric cancer.
- •Age ≥ 18 years or age of consent in country of residence and able to sign Informed Consent
- •ECOG performance status of 0-1 at study entry
- •HER2-overexpressing positive gastric tumor by IHC3+ or IHC2+ with positive in situ hybridization
- •Measurable disease according to RECIST (Irradiated lesions can not be considered measurable unless they have clearly progressed since radiotherapy).
- •Negative serum pregnancy test. The serum pregnancy test must be obtained prior to any drug administration (≤ 72 hours prior to dosing) in all pre-menopausal women and for women < 2 years after the onset of menopause.
- •Patients must have the following laboratory values:
- •Hematologic
- •Absolute Neutrophil Count (ANC) ≥1.5x109/L,
- •Hemoglobin (Hgb) ≥ 9 g/dL,
- •Platelets (plt) ≥100x109/L
- •Biochemistry:
- •Serum total bilirubin ≤ 1.5 x ULN
- •Serum albumin > 2.5 g/dl
- •Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 ml/min.
- •AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 x ULN if liver metastases are present
排除标准
- •Patients eligible for this study must not meet any of the following criteria:
- •Evidence of spinal cord compression or current evidence of CNS metastases. CT/MRI of the brain is mandatory (within 3 weeks before study start) in case of clinical suspicion or evidence of brain metastases
- •Patient who are < 4 weeks since last chemotherapy or treatment with another systemic anti-cancer agent. Patients must have recovered (CTC ≤ 1) from acute toxicities of any previous therapy (with the exception of alopecia).
- •Patients may have received prior radiotherapy for management of local disease providing that disease progression has been documented, all toxicities have resolved (CTC ≤ 1) (with the exception of alopecia), and the last fraction of radiotherapy was completed at least 4 weeks prior to the study.
- •Prior treatment with an agent that acts via HER2/c-erbB2 targeting other than 1st line trastuzumab, include (but are not limited to) lapatinib and pertuzumab.
- •Treatment with therapeutic doses of coumarin-type anticoagulants. (Maximum daily dose of 2 mg, for line patency permitted)
- •Patients with malignant ascites that require invasive treatment
- •Patients with acute or chronic renal disease; and active and chronic liver disease requiring intervention. Other concurrent severe and/or uncontrolled medical conditions that could cause unacceptable safety risks or compromise compliance with the protocol.
- •Major surgery ≤ 2 weeks prior to enrollment or who have not recovered from such therapy
- •Impaired cardiac function
- •Concurrent malignancies or invasive cancers diagnosed within the past 5 years, except for adequately treated basal cell cancer of the skin or in situ cancer of the cervix
- •Patients receiving chronic or high dose corticosteroids therapy (Inhaled steroids and short courses of oral steroids for anti-emesis or as an appetite stimulant are allowed)
- •Patients unwilling or unable to comply with the protocol
- •Patients known to be HIV positive. Testing is not required in the absence of clinical signs and symptoms suggesting HIV infection.
- •Known hypersensitivity to any of the study drugs or their excipients
- •Participation in another clinical study within 30 days before first study treatment
- •Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL).
- •Fertile women of childbearing potential (WOCBP) not using adequate contraception (abstinence, oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile).
研究组 & 干预措施
AUY922 + Trastuzumab
Experimental
干预措施: AUY922 (Drug)
AUY922 + Trastuzumab
Experimental
干预措施: Trastuzumab (Drug)
结局指标
主要结局
efficacy of AUY922 in combination with trastuzumab as assessed by RECIST
时间窗: every 6 weeks
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Phase II Trial of AUY922 vs. Comparators in Advanced Gastric CancerAdvanced Gastric CancerGastro-esophageal Junction CancerNCT01084330Novartis Pharmaceuticals68
终止
2 期
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR MutationsAdvanced Non Small Cell Lung Cancer (NSCLC)NCT01646125Novartis Pharmaceuticals59
已完成
1 期
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.Relapsed or Refractory Multiple MyelomaNCT00708292Novartis Pharmaceuticals29
已完成
1 期
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With TrastuzumabAdvanced HER2-positive Breast CancerNCT01271920Novartis Pharmaceuticals45
已完成
2 期
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.Non-small-cell Lung CancerNCT01124864Novartis Pharmaceuticals153